Zacks Research Issues Pessimistic Forecast for TEVA Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Investment analysts at Zacks Research lowered their Q2 2026 EPS estimates for shares of Teva Pharmaceutical Industries in a research note issued on Monday, April 28th. Zacks Research analyst R. Department now forecasts that the company will earn $0.60 per share for the quarter, down from their prior forecast of $0.62. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q3 2026 earnings at $0.78 EPS, Q4 2026 earnings at $0.70 EPS, FY2026 earnings at $2.56 EPS, Q1 2027 earnings at $0.60 EPS and FY2027 earnings at $2.77 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%.

TEVA has been the topic of a number of other reports. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a “strong-buy” rating in a research report on Monday. UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Piper Sandler lifted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, April 23rd. Finally, Bank of America cut their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Trading Up 0.8 %

Teva Pharmaceutical Industries stock opened at $15.64 on Thursday. The business has a 50 day moving average price of $15.11 and a two-hundred day moving average price of $17.51. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries has a 12 month low of $12.47 and a 12 month high of $22.80. The stock has a market cap of $17.73 billion, a price-to-earnings ratio of -10.78, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently added to or reduced their stakes in TEVA. Diversify Advisory Services LLC lifted its position in shares of Teva Pharmaceutical Industries by 2.5% during the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company’s stock worth $426,000 after purchasing an additional 496 shares in the last quarter. Thrivent Financial for Lutherans raised its position in Teva Pharmaceutical Industries by 0.3% in the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company’s stock worth $4,964,000 after purchasing an additional 699 shares during the last quarter. Bfsg LLC lifted its holdings in Teva Pharmaceutical Industries by 7.8% during the 1st quarter. Bfsg LLC now owns 10,960 shares of the company’s stock worth $168,000 after buying an additional 790 shares in the last quarter. Townsquare Capital LLC boosted its position in Teva Pharmaceutical Industries by 2.1% in the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company’s stock valued at $885,000 after buying an additional 812 shares during the last quarter. Finally, Metis Global Partners LLC increased its stake in shares of Teva Pharmaceutical Industries by 6.7% in the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company’s stock valued at $302,000 after buying an additional 860 shares during the period. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.